Natixis Advisors L.P. Sells 3,523 Shares of Humana Inc. (NYSE:HUM)

Natixis Advisors L.P. lessened its holdings in Humana Inc. (NYSE:HUM) by 4.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 68,750 shares of the insurance provider’s stock after selling 3,523 shares during the period. Natixis Advisors L.P.’s holdings in Humana were worth $31,474,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Rakuten Securities Inc. bought a new position in Humana in the fourth quarter worth approximately $25,000. Gradient Investments LLC raised its position in shares of Humana by 200.0% in the 4th quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 40 shares in the last quarter. Cetera Trust Company N.A bought a new position in shares of Humana in the 4th quarter worth $28,000. Nvwm LLC lifted its stake in shares of Humana by 41.0% during the 3rd quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock worth $42,000 after purchasing an additional 25 shares during the last quarter. Finally, Turtle Creek Wealth Advisors LLC bought a new stake in Humana during the fourth quarter valued at about $55,000. 92.38% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on HUM shares. Barclays decreased their price target on shares of Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 2nd. Stephens cut their price target on shares of Humana from $550.00 to $430.00 and set an “overweight” rating on the stock in a report on Friday, January 26th. Jefferies Financial Group reduced their price target on Humana from $411.00 to $381.00 and set a “buy” rating on the stock in a research report on Monday, April 22nd. TD Cowen lowered their price objective on Humana from $427.00 to $396.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. Finally, Deutsche Bank Aktiengesellschaft lowered Humana from a “buy” rating to a “hold” rating and reduced their target price for the company from $595.00 to $360.00 in a research report on Thursday, January 25th. Eleven equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $424.50.

Insider Activity

In related news, Director Jorge S. Mesquita bought 545 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The shares were purchased at an average cost of $367.09 per share, with a total value of $200,064.05. Following the completion of the acquisition, the director now directly owns 2,578 shares in the company, valued at $946,358.02. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.32% of the company’s stock.

Humana Price Performance

Shares of NYSE HUM opened at $320.54 on Friday. Humana Inc. has a 52 week low of $298.61 and a 52 week high of $541.21. The business’s 50 day moving average price is $324.12 and its 200 day moving average price is $388.34. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.77. The firm has a market cap of $38.63 billion, a P/E ratio of 19.96, a P/E/G ratio of 1.86 and a beta of 0.49.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, beating the consensus estimate of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The business had revenue of $29.61 billion for the quarter, compared to the consensus estimate of $28.52 billion. During the same period in the prior year, the firm earned $9.38 EPS. The business’s revenue for the quarter was up 10.7% on a year-over-year basis. On average, sell-side analysts expect that Humana Inc. will post 16.18 earnings per share for the current year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.10%. Humana’s payout ratio is currently 22.04%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.